Hep druginteractions org

Hep druginteractions org

We have produced a series of printable materials in PDF format to aid prescribing.

Interaction Charts provide an overview of interactions between HCV DAAs and the comedications listed in the interaction checker.

Treatment Selectors show interactions between key HCV DAAs and drugs used to treat a range of common comorbidities or specific patient populations.

Fact Sheets contain information on the pharmacokinetics, metabolism and disposition of drugs used to treat viral hepatitis and have been collated from product labels and published literature on licensed doses (unless otherwise stated). Please click on the headings below to see the full range of resources within each section.

HEP Drug Interactions

Download from the AppStore

Download from Google Play

Summary:

Coadministration of omeprazole (20 mg once daily) simultaneously with ledipasvir/sofosbuvir (90/400 mg single dose) decreased ledipasvir Cmax and AUC by 11% and 4%, increased sofosbuvir Cmax by 12% and no effect on sofosbuvir AUC. Omeprazole 20 mg or lower can be administered simultaneously with ledipasvir/sofosbuvir under fasted conditions. Proton pump inhibitors should not be taken before ledipasvir/sofosbuvir.

Description:

View all available interactions with Ledipasvir/Sofosbuvir by clicking here.

Last Review: October 13, 2019

Copyright © 2019 The University of Liverpool. All rights reserved.

HEP Drug Interactions

Download from the AppStore

Download from Google Play

HEP Drugs

Selected HEP Drugs will be displayed here.

Co-medications

Selected Co-medications will be displayed here

Drug Interactions

Check HEP/ HEP drug interactions

Drug Interactions will be displayed here

Look for alternatives

Summary:

Description:

Summary:

Description:

Open in new tab

Do Not Coadminister

Potential Weak Interaction

Читайте также:  Вагинальные кольца цена

No Interaction Expected

Clicking on a symbol will give further information on the interaction.

If a combination has not been assessed (either by study or within the product label), an interaction has been predicted based on the metabolic profiles of the drugs.

These drugs should not be coadministered

Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration.

Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required

No clinically significant interaction expected

Ссылка на основную публикацию
Hcv core положительный что это значит
На протяжении жизни организм человека атакуется всевозможными вирусами. К опасным относится вирус гепатита С, поражающий печень. За последние 10 лет...
Adblock detector